Nine Masts Capital’s Inovio Pharmaceuticals INO Stock Holding History

Nine Masts Capital’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-26,317	Closed	-$45.8K	–	234
2026 Q1	$45.8K	Buy	+26,317	New	+$43.3K	0.01%	151

Other funds holding INO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nine Masts Capital's INO Position: Q2 2026 in Review

Nine Masts Capital sold out of Inovio Pharmaceuticals (INO) in Q2 2026, closing a stake of 26,317 shares — an estimated $45.8K sold.

Nine Masts Capital first reported a position in INO in Q1 2026 and held it in 1 quarter. The position peaked at $45.8K in Q1 2026. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

Nine Masts Capital reported no remaining Inovio Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Nine Masts Capital sold 26,317 Inovio Pharmaceuticals shares in Q2 2026, an estimated $45.8K.
Nine Masts Capital first reported a position in Inovio Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Nine Masts Capital's Inovio Pharmaceuticals position peaked at $45.8K in Q1 2026.
103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.